DexCom (NASDAQ:DXCM)‘s stock had its “buy” rating reaffirmed by stock analysts at Piper Jaffray Companies in a research note issued on Monday.
Several other equities analysts have also recently weighed in on DXCM. BidaskClub raised shares of DexCom from a “hold” rating to a “buy” rating in a research note on Friday. ValuEngine cut shares of DexCom from a “hold” rating to a “sell” rating in a research note on Wednesday, March 7th. Northcoast Research reissued a “buy” rating on shares of DexCom in a research note on Sunday, March 4th. Zacks Investment Research cut shares of DexCom from a “hold” rating to a “sell” rating in a research note on Friday, March 2nd. Finally, Oppenheimer set a $67.00 target price on shares of DexCom and gave the company a “buy” rating in a research note on Wednesday, February 28th. Three analysts have rated the stock with a sell rating, six have assigned a hold rating and fourteen have assigned a buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $65.97.
Shares of DexCom (NASDAQ DXCM) traded up $2.96 on Monday, hitting $63.09. 1,131,949 shares of the stock traded hands, compared to its average volume of 1,256,283. The company has a market cap of $5,231.14, a PE ratio of -106.71 and a beta of 0.27. DexCom has a one year low of $42.62 and a one year high of $86.32. The company has a quick ratio of 5.04, a current ratio of 5.36 and a debt-to-equity ratio of 0.78.
In other DexCom news, insider Terrance H. Gregg sold 10,000 shares of DexCom stock in a transaction on Tuesday, January 16th. The shares were sold at an average price of $56.86, for a total transaction of $568,600.00. Following the completion of the transaction, the insider now directly owns 484,559 shares of the company’s stock, valued at $27,552,024.74. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO Kevin R. Sayer sold 6,000 shares of DexCom stock in a transaction on Tuesday, December 12th. The stock was sold at an average price of $58.85, for a total transaction of $353,100.00. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 30,908 shares of company stock valued at $1,754,635. Company insiders own 1.70% of the company’s stock.
Institutional investors and hedge funds have recently bought and sold shares of the company. American International Group Inc. acquired a new stake in shares of DexCom during the fourth quarter worth $116,000. Thompson Davis & CO. Inc. acquired a new stake in shares of DexCom during the fourth quarter worth $137,000. The Manufacturers Life Insurance Company lifted its holdings in shares of DexCom by 12.2% during the second quarter. The Manufacturers Life Insurance Company now owns 3,254 shares of the medical device company’s stock worth $238,000 after buying an additional 354 shares in the last quarter. Zions Bancorporation lifted its holdings in shares of DexCom by 36,222.2% during the third quarter. Zions Bancorporation now owns 3,269 shares of the medical device company’s stock worth $160,000 after buying an additional 3,260 shares in the last quarter. Finally, Marco Investment Management LLC acquired a new stake in shares of DexCom during the fourth quarter worth $201,000.
TRADEMARK VIOLATION WARNING: “DexCom (DXCM) Stock Rating Reaffirmed by Piper Jaffray Companies” was originally posted by Markets Daily and is the sole property of of Markets Daily. If you are accessing this piece on another publication, it was illegally copied and republished in violation of U.S. and international trademark & copyright law. The legal version of this piece can be viewed at https://www.themarketsdaily.com/2018/03/12/dexcom-dxcm-stock-rating-reaffirmed-by-piper-jaffray-companies.html.
Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company’s products consist of DexCom G4 PLATINUM and DexCom G5 Mobile.
Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.